← Eichor
Study identifier: NCT06959810 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Impact of Adapted Aesthetic Onco in Patients With Upper Aerodigestive Tract Cancer During Their Management

Condition: Oncology · Aerodigestive Tract Cancer · Suportive Care  ·  Sponsor: Centre Francois Baclesse

PhaseNA
Planned participants55
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Treatment for cancers of the pharyngolarynx is mutilating, with major consequences for patients' lives in terms of physical and functional after-effects. The psycho-social consequences are also significant, notably the metamorphosis of identity linked to the disease and its treatment, which alters the patient's self-image. Initial feedback from patients who have been able to benefit from adapted oncoesthetics (OEA) is overwhelmingly positive. This study will assess the feasibility of oncoesthetics and describe any obstacles.

This description comes directly from the study's public registry record.

Talk to the study team

Marielle RENOU, Care Manager  ·  33231455050  ·  m.renou@baclesse.unicancer.fr

Francois GERNIER, Care Manager  ·  33231455050  ·  f.gernier@baclesse.unicancer.fr

Always discuss trial participation with your own doctor first.

Locations (1)

Centre Francois BaclesseCaen, FranceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06959810